ONO-4578 (Not yet branded)
Other Medications
Description
ONO-4578 is a novel therapeutic agent being developed for metastatic colorectal cancer, specifically in patients with microsatellite instability-high (MSI-H) tumors. This compound is administered in combination regimens that include established therapies such as nivolumab (Opdivo), mFOLFOX6 chemotherapy, and bevacizumab for enhanced antitumor activity. Based on current clinical development, ONO-4578 appears to be designed to work synergistically with immunotherapy and standard chemotherapy combinations in the metastatic CRC setting.
Mechanism of Action
ONO-4578's specific molecular mechanism of action has not been fully disclosed in publicly available information. The drug is being studied in combination with immune checkpoint inhibitors and chemotherapy, suggesting it may modulate immune responses or enhance the efficacy of existing therapeutic approaches in MSI-H colorectal tumors.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.